Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-01

Study Completion Date

2022-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular diseases. Pharmacological experiments confirmed that AngongNiuhuang pill can protect blood-brain barrier, inhibit capillary permeability, improve the tolerance of cerebral ischemia and hypoxia, reduce oxidative stress injury, thus protecting brain tissue. Clinical studies have also confirmed that AngongNiuhuang pill can increase the GCS score, reduce coma, improve nerve function defect and promote nerve function recovery. The primary purpose of this trial was to evaluate the difference in the volume of cerebral infarction and cerebral edema between Angong Niuhuang pill and placebo in patients with ischemic stroke at 14 days compared with the baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.

NCT03733002

Acute Ischemic Stroke

UNKNOWN PHASE3

Danhong Injection in the Treatment of Acute Ischemic Stroke

NCT01677208

Acute Stroke

COMPLETED PHASE4

Urokinase for Thrombolysis in Acute Ischemic Stroke

NCT07047326

Acute Ischemic Stroke

RECRUITING NA

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

NCT06344312

Stroke, Acute Ischemic

ACTIVE_NOT_RECRUITING NA

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial

NCT03578822

Acute Ischaemic Stroke

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective, randomized, double-blinded, placebo parallel controlled, multicenter trial. Patients who met the inclusion and exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive AngongNiuhuang pill 1pill qd/day for 5-day; 2) the other group will receive Placebo of AngongNiuhuang pill 1pill qd/day for 5-day. The primary purpose of this trial was to evaluate the difference in the volume of cerebral infarction and cerebral edema between Angong Niuhuang pill and placebo in patients with ischemic stroke at 14 days compared with the baseline. The study was consisted of six visits, including the day of randomization, 2 days, 3-6 days, 7 days (the endap time of the therapy), 14 days, and 90 days (the endap time of the follow-up). Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The period of the trial is from August 2020 to October 2021, and 120 subjects are planned to be recruited from 10 centers in China. All the related investigative organizations and individuals will obey the Declaration of Helsinki and Chinese Guard-cell protoplast (GCP) standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AngongNiuhuang

Drugs : AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.

Group Type EXPERIMENTAL

AngongNiuhuang pill

Intervention Type DRUG

This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.

Standard treatment

Intervention Type OTHER

The other treatments according to guidelines for standard treatment of acute ischemic stroke

Placebo of AngongNiuhuang

Drugs : Placebo of AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.

Group Type PLACEBO_COMPARATOR

Placebo of AngongNiuhuang pill

Intervention Type DRUG

This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.

Standard treatment

Intervention Type OTHER

The other treatments according to guidelines for standard treatment of acute ischemic stroke

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AngongNiuhuang pill

This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.

Intervention Type DRUG

Placebo of AngongNiuhuang pill

This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.

Intervention Type DRUG

Standard treatment

The other treatments according to guidelines for standard treatment of acute ischemic stroke

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Angong Niuhuang Wan Placebo of Angong Niuhuang Wan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female participates aged 40-80 years.
2. Diagnosis with acute ischemic stroke.
3. Diagnosis with acute cerebral infarctions of internal carotid artery system.
4. 10≤ Baseline NIHSS \<20.
5. Time of onset ≤36h.
6. Provision of informed consent.

Exclusion Criteria

1. Not suitable for taking this medicine according to the judgement of consulting traditional Chinese medical doctor.
2. Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other brain organic diseases.
3. Patients with hemorrhagic transformation after cerebral infarction.
4. Received or planned to receive endovascular treatment, including thrombectomy, ultra early thrombectomy and stenting.
5. Received or planned to receive decompression craniectomy.
6. With mRS score \>1 before onset of this episode.
7. Participates who cannot tolerate the MRI scans, such as Using a pacemaker or automatic defibrillator or having claustrophobia.
8. With thrombocytopenia (\<100 x10\^9/L), hematologic diseases or other systemic bleeding tendency.
9. With Alanine transaminase or Aspartate aminotransferase \>1.5 times than normal upper limit or Creatinine \>1.5 times than normal upper limit.
10. Allergic to ingredients of AngongNiuhuang pill.
11. Received AngongNiuhuang pill within 1 month.
12. Participates who plan to become pregnant within 3 months, or women of childbearing age with negative pregnancy test but refuse to accept contraception; during pregnancy or lactation.
13. Participates in other clinical trials within 30 days before randomization or currently involved in other clinical trails.
14. Participates with a life expectancy less than 3 months.
15. Incapable to follow this study due to mental illness, cognitive or emotional disorders.
16. Participates are not eligible for this clinical trial as evaluated by the investigators.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No